KMTS KESTRA MEDICAL TECHNOLOGIES, LTD.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1877184 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY60.7%
TTM net income YoY-25.1%
TTM EPS YoY40.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin53.9%
Operating margin-134.5%
Net margin-140.4%
FCF margin-115.0%
EBITDA margin-125.7%
Returns
ROE-73.7%
ROA-48.8%
ROIC (approx.)-90.4%
Asset turnover0.35x
Leverage & solvency
Liabilities / assets36.0%
Debt / equity0.33x
Current ratio4.69x
Interest coverage-18.98x
Cash quality & payout
Operating cash flow / net income0.59x
Accruals ratio-20.3%
Payout ratio—
Capex / revenue32.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q12026-07-31 | 2026Q4*2026-04-30 | 2026Q32026-01-31 | 2025Q22025-10-31 | 2025Q12025-07-31 | 2025Q4*2025-04-30 | 2025Q32025-01-31 | 2025Q22024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $30.97M | $28.64M | $24.55M | $22.57M | $19.37M | $17.23M | $15.09M | $14.71M |
| Cost of revenue | $13.47M | $12.96M | $11.65M | $11.14M | $10.52M | $9.60M | $8.54M | $8.88M |
| Gross profit | $17.50M | $15.68M | $12.91M | $11.42M | $8.85M | $7.63M | $6.55M | $5.83M |
| R&D expense | $6.80M | $5.63M | $4.97M | $4.88M | $4.00M | $5.39M | $3.35M | $3.51M |
| SG&A expense | $48.36M | $49.39M | $42.70M | $38.30M | $33.73M | $50.46M | $23.80M | $21.45M |
| Operating income | -$37.66M | -$39.34M | -$34.77M | -$31.75M | -$28.88M | -$48.21M | -$20.60M | -$19.13M |
| Interest expense | $1.93M | $1.84M | $1.89M | $1.90M | $1.91M | $1.76M | $1.78M | $2.32M |
| Pretax income | -$44.04M | -$38.64M | -$34.13M | -$32.75M | -$25.79M | -$51.01M | -$21.74M | -$20.61M |
| Income tax | $50,000 | $192,000 | $35,000 | $34,000 | $33,000 | $102,000 | $18,000 | $8,000 |
| Net income | -$44.09M | -$38.84M | -$34.17M | -$32.78M | -$25.83M | -$52.05M | -$21.51M | -$20.37M |
| EBITDA | -$34.99M | -$37.02M | -$32.78M | -$29.38M | -$26.85M | -$46.38M | -$18.71M | -$17.27M |
| EPS (basic) | -0.75 | — | -0.61 | -0.64 | -0.50 | — | -1.25 | -1.19 |
| EPS (diluted) | -0.75 | — | -0.61 | -0.64 | -0.50 | — | -1.25 | -1.19 |
| Weighted avg. shares (diluted) | 58.57M | — | 55.85M | 51.38M | 51.30M | — | 19.89M | 19.89M |
| Balance sheet | ||||||||
| Cash & equivalents | $68.56M | $99.71M | $291.32M | $175.42M | $201.21M | $237.93M | $54.35M | $76.92M |
| Short-term investments | $130.35M | $96.72M | — | — | — | — | — | — |
| Receivables | $15.41M | $14.54M | $12.71M | $10.41M | $9.25M | $8.08M | — | — |
| Current assets | $226.27M | $222.36M | $314.06M | $195.41M | $220.69M | $255.33M | — | — |
| PP&E, net | $63.66M | $59.09M | $53.80M | $45.93M | $40.38M | $34.83M | — | — |
| Total assets | $347.36M | $358.46M | $379.34M | $246.70M | $266.30M | $295.74M | — | — |
| Current liabilities | $48.27M | $50.37M | $42.93M | $35.76M | $32.26M | $37.98M | — | — |
| Long-term debt | $72.50M | $42.65M | $42.26M | $41.87M | $41.49M | $41.10M | — | — |
| Total debt | $72.50M | $42.65M | $42.26M | $41.87M | $41.49M | $41.10M | — | — |
| Total liabilities | $125.00M | $98.81M | $91.35M | $82.62M | $82.14M | $90.34M | — | — |
| Shareholders' equity | $222.36M | $259.66M | $287.99M | $164.08M | $184.16M | $205.41M | -$257.89M | -$236.54M |
| Net debt | $3.94M | -$57.06M | -$249.06M | -$133.55M | -$159.73M | -$196.83M | — | — |
| Shares outstanding | 59.27M | 58.38M | 58.35M | 51.45M | 51.35M | 51.35M | 100 | — |
| Cash flow statement | ||||||||
| Operating cash flow | -$32.30M | -$18.72M | -$18.37M | -$18.34M | -$26.27M | -$24.06M | -$18.00M | -$18.06M |
| Capital expenditure | $8.34M | $9.66M | $9.80M | $7.26M | $8.17M | $7.39M | $4.06M | $4.45M |
| Free cash flow | -$40.63M | -$28.38M | -$28.16M | -$25.61M | -$34.44M | -$31.45M | -$22.06M | -$22.50M |
| Investing cash flow | -$21.35M | -$172.71M | -$14.92M | -$7.42M | -$8.23M | -$7.40M | -$4.45M | -$4.42M |
| Financing cash flow | $22.50M | -$185,000 | $149.18M | -$27,000 | -$1.88M | $214.70M | -$119,000 | -$575,000 |
| Depreciation & amortization | $2.66M | $2.33M | $1.98M | $2.37M | $2.03M | $1.84M | $1.89M | $1.87M |
| Stock-based compensation | $9.52M | $10.30M | $10.11M | $8.65M | $4.58M | $22.31M | $459,000 | $1.12M |
Free plan shows the latest 8 periods; Pro shows all 9 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.